Login to Your Account

Lilly Bolsters Diagnostics Capabilities with Avid Buy

By Donna Young

Tuesday, November 9, 2010
Seeking to build on its neuroscience product development program, Eli Lilly and Co. has put $300 million on the table to buy privately held Avid Radiopharmaceuticals Inc., a Philadelphia-based firm that develops molecular imaging compounds, including florbetapir F 18 (18F-AV-45), an investigational agent used to detect the presence of amyloid plaque in the brain – a hallmark sign of Alzheimer's disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription